REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Preparations Characterized By Special Physical Form > Implant Or Insert > Ocular OcularOcular patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.07/05/07 - 20070154525 - Apparatus and method for preventing adhesions between an implant and surrounding tissues An anti-adhesion membrane is placed onto an implant introduced into a surgical site of a patient to prevent post-surgical adhesions between the implant and surrounding tissue. The implant may comprise either biological material, such as a transplanted organ, or non-biological material such as a medical device. The membrane may be ... 07/05/07 - 20070154524 - Micronized device for the delivery of biologically active molecules and methods of use thereof The invention provides micronized encapsulated cell therapy devices that are capable of delivering a biologically active molecule to the eye. Also provided are methods of using the same to deliver biologically active molecules to the eye and to treat ophthalmic disorders in patients suffering there from. ... 07/05/07 - 20070154523 - Controlled pupil dilation for diagnostic and treatment of visual anomalies Methods and compositions are disclosed for topically applying an ophthalmic solution to the eye to at least temporarily reduce the effects of various visual anomalies. The solution contains a therapeutically effective amount of one or more pupil dilating agents that generate a moderate amount of dilation in order to relieve ... 07/05/07 - 20070154522 - Polymer having interconnected pores for drug delivery and method A bicontinuous microemulsion of water, a monomer, and a surfactant copolymerizable with the monomer is polymerized to form a transparent and porous polymer defining interconnected pores. The pores may have a pore diameter in the range of 10 to 100 mm. The microemulsion may further include a drug such that, ... 06/28/07 - 20070148208 - Anti-excititoxic sustained release intracular implants and related methods Biocompatible intraocular implants include an anti-excitotoxic agent and a biodegradable polymer that is effective to facilitate release of the anti-excitotoxic agent into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is ... 06/21/07 - 20070141117 - Anti-excititoxic sustained release intraocular implants and related methods Biocompatible intraocular implants include an anti-excitotoxic agent and a biodegradable polymer that is effective to facilitate release of the anti-excitotoxic agent into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is ... 06/21/07 - 20070141116 - Glaucoma implant device An aqueous humor drainage device having an elongate duct structure that provides a fluid passageway for diverting aqueous humor from the anterior chamber of the eye and at least one fixation member that extends from the elongate duct structure. In one embodiment, the fixation member is realized by a tab ... 06/21/07 - 20070141115 - Drug delivery systems wherein x, y, m, m′, R, R1, R2, R3, R4, R5, R6, R7, X, Z and Z′ are as defined herein are provided, wherein the matrix controlled diffusion drug delivery systems are sized and configured for back of the eye delivery. ... 04/26/07 - 20070092550 - Methods and compositions for growing corneal endothelial and related cells on biopolymers and creation of artifical corneal transplants This invention discloses methods to attach and grow a monolayer of cultured human corneal endothelial cells onto the endothelial side of the stroma synthesized from biopolymer to generate a more bio-equivalent artificial cornea. The approaches will include the use of attachment and growth promoting agents such as fibronectin, laminin, RGDS, ... 04/05/07 - 20070077278 - Polysaccharide-containing composition and tear film stabilizing ophthalmic solution An object of the present invention is to provide a composition which is excellent in safety and capable of dispersing uniformly on the mucous tissue when topically administered to mammals, and an ophthalmic solution comprising the composition and capable of stabilizing the tear film and keeping the tear film on ... 03/29/07 - 20070071792 - In vivo formed matrices including natural biodegradale polysaccharides and ophthalmic uses thereof In vivo formed matrices including natural biodegradable polysaccharides are described. The matrix is formed from a plurality of natural biodegradable polysaccharides having pendent coupling groups. The matrix can also include a bioactive agent that can be released to provide a therapeutic effect to a patient. The formed matrices are particularly ... 02/08/07 - 20070031472 - Steroid-containing sustained release intraocular implants and related methods Biocompatible intraocular implants include a steroid and an auxiliary agent, where the auxiliary agent is present in an amount sufficient to lessen the severity of at least one side effect compared to the use of an otherwise identical implant lacking said auxiliary agent. The steroid and the auxiliary agent may ... 02/08/07 - 20070031471 - Uses of amniotic membranes as biocompatible devices Amniotic membranes provided as emulsions to provide desirable features. The emulsion, containing micron or submicron sized particles of amniotic membrane, is formulated to increase absorption and overall bioavailability. In one embodiment, the emulsion is sprayed onto an implantable or insertable medical device. In another embodiment, the emulsion is sprayed onto ... 02/01/07 - 20070026048 - Implantable drug delivery device The invention is directed to an implantable device to enable delivery of drugs to the retina. The device minimizes stress to the retina by virtue of its softness and smooth shape that conform to the retina. Drugs are delivered by osmosis or by the device dissolving. It may be connected ... 02/01/07 - 20070026047 - Thermal effect on crystalinity for drug delivery devices A drug delivery device for placement in the eye includes a drug core comprising a pharmaceutically active agent, and a holder that holds the drug core. The holder is made of a material impermeable to passage of the active agent and includes an opening for passage of the pharmaceutically agent ... 02/01/07 - 20070026046 - Neoglycopolymer-cross-linked biopolymer matrix The present application provides a cross-linked biopolymer matrix, or scaffold, comprising a biopolymer and cross-linked with a neoglycopolymer. A specific example of a biopolymer matrix according to this invention comprises collagen as the biopolymer. Also provided is a method for producing the cross-linked biopolymer matrix and methods of use thereof. ... 01/18/07 - 20070014833 - Treatment of eye disorders with sirtuin modulators Sirtuin modulators, particularly sirtuin activators, are useful in treating vision impairment. In general, the sirtuin modulators inhibit the progression of vision impairment resulting from various eye disorders. The invention also includes pharmaceutically acceptable formulations of sirtuin modulators, particular ophthalmically acceptable formulations. ... 12/28/06 - 20060292203 - Methods and compositions for the treatment of ocular disorders The invention provides methods and compositions for the delivery of lipophilic drugs that are useful for the treatment of various ophthalmological diseases, disorders, and pathologies, including the treatment of age-related macular degeneration, diabetic retinopathy, diabetic macular edema, cancer, and glaucoma. ... 12/28/06 - 20060292202 - Drug delivery device Drug delivery devices include a beta-carboline active agent for treatment of ophthalmic disorders. ... 12/21/06 - 20060286148 - Method of forming implants The present invention is a method for producing an implant for a corneal pocket assay by introducing a solution into a perforated plate or member, allowing the solution to form pellets, and removing the pellets from the perforations. The present invention also includes a method for performing a corneal pocket ... 12/21/06 - 20060286147 - High refractive-index, hydrophilic, arylsiloxy-containing monomers and polymers, and ophthalmic devices comprising such polymers Hydrophilic, arylsiloxy-containing monomers and macromonomers have at least a terminal hydrophilic group attached to an arylsiloxy group. The aryl groups attached to siloxy groups can be substituted with other hydrophilic groups. Polymers comprising such hydrophilic, arylsiloxy-containing monomers and macromonomers avoid or reduce the risk of forming vacuoles of absorbed water. ... 11/23/06 - 20060263409 - Treatment of ocular disease A formulation to treat ocular conditions such as dry eye disease, as well as other conditions, is disclosed. Rapamycin and/or ascomycin is administered intraocularly, such as by topical application, injection into the eye, or implantation in or on the eye. For example, a topical administration may contain between about 50 ... 11/16/06 - 20060257452 - Ocular therapy using alpha-2 adrenergic receptor anterior compounds having enhanced clearance rates Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component which includes an alpha 2 adrenergic receptor agonist that is cleared from the anterior segment of an individual's eye to which the material is administered. The alpha 2 adrenergic receptor agonist may have a ... 11/16/06 - 20060257451 - Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease The invention relates to sustained release implants and to methods for treating eyes, particularly the eyes of mammals having eye disorders or diseases. By using the implants and methods described herein, the delivery of the one or more bioactive agents can be localized at a desired treatment site, particularly the ... 11/16/06 - 20060257450 - Drug delivery systems for treatment of diseases or conditions Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are solid drug delivery systems and methods for providing extended delivery of ... 11/02/06 - 20060246113 - Bio-synthetic matrix and uses thereof A bio-synthetic matrix comprising a hydrogel which is formed by cross-linking a synthetic polymer and a bio-polymer is provided. The matrix is robust, biocompatible and non-cytotoxic and is capable of supporting cell in-growth in vivo. The matrix can be tailored to further comprise one or more bioactive agents. The matrix ... 11/02/06 - 20060246112 - Sustained release ophthalmological device and method of making and using the same An ophthalmological implant including a layer of pharmaceutical agent and an overlying layer of a bioerodible material, a biodegradable material a bioavailable material or a mixture thereof. ... 11/02/06 - 20060246111 - Polysaccharides as ultrasound transmission media Ultrasound couplants comprising polysaccharides, particularly sodium alginate and chitosan, and compatible substances for ultrasound imaging in applications that require either sterile or non-sterile forms of ultrasound transmission gels or liquids. ... 10/26/06 - 20060240073 - Structure of modulating intraocular pressure on glaucoma A 3D porous structure is designed for modulating intraocular pressure on glaucoma. The 3D porous structure includes collagen and glycosaminoglycan in the form of copolymer, wherein the collagen and the glycosaminoglycan have a 10:1 ratio in weight and the copolymer has a percentage in the range of 0.125% to 8%. ... 10/19/06 - 20060233860 - Alpha-2 agonist polymeric drug delivery systems Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, ... 10/19/06 - 20060233859 - Methods for treating retinopathy with extended therapeutic effect Methods for treating and preventing retinopathic conditions by administering a glucocorticoid to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy. ... 10/19/06 - 20060233858 - Systems and methods providing targeted intraocular drug delivery Drug delivery systems suitable for administration into the interior of an eye of a person or animal are described. The present systems include a drug delivery element that provides directional delivery of one or more drugs to a desired target site in the eye and remain invisible to the individual ... 10/12/06 - 20060228394 - Ocular solutions Ocular solutions containing at least one macrolide antibiotic and/or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial, and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surgery before insertion of a replacement intraocular lens, resulting in reduced posterior capsular opacification which may eliminate the ... 10/12/06 - 20060228393 - Ocular solutions Ocular solutions containing at least one macrolide antibiotic and/or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial, and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surgery before insertion of a replacement intraocular lens, resulting in reduced posterior capsular opacification which may eliminate the ... 09/28/06 - 20060216328 - Topical composition comprising a cyclofructan, a carrier and a drug The present invention relates in particular to a drug delivery system comprising a cyclofructan, a drug and a polymeric carrier. ... 09/21/06 - 20060210604 - Ocular delivery of polymeric delivery formulations The present invention provides a flowable composition suitable for use as a controlled release implant. The flowable composition can be administered into the ocular region of a mammal. The composition includes: (a) a biodegradable, biocompatible thermoplastic polymer that is at least substantially insoluble in aqueous medium, water or body fluid; ... 09/14/06 - 20060204548 - Microimplants for ocular administration Implants and microimplants are provided comprising homogeneous mixtures of active ingredient and bioerodible polymer, including microimplants having diameters of 0.019 inches or less and which can be delivered to the eye using self-sealing methods. Methods of manufacturing the implants and microimplants are provided that yield batches of highly uniform implants ... 09/07/06 - 20060198871 - Methods for treating neovascularization and intravitreal implants Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer. ... 08/31/06 - 20060193894 - Methods for providing biomedical devices with hydrophilic antimicrobial coatings The invention provides a process for producing devices with stable surface coatings, which coatings are one or both of hydrophilic and antimicrobial. ... 08/17/06 - 20060182783 - Sustained release intraocular drug delivery systems Biocompatible intraocular drug delivery systems include a anti-angiogenic macromolecular therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its ... 08/10/06 - 20060177483 - Contact drug delivery system A drug delivery system is disclosed. The drug delivery system includes a recognitive polymeric hydrogel through which a drug is delivered by contacting biological tissue. The recognitive polymeric hydrogel is formed using a bio-template, which is a drug or is structurally similar to the drug, functionalized monomers, preferably having coamplexing ... 08/03/06 - 20060171991 - Method for stromal corneal repair and refractive alteration A method and means of providing stromal repair and improved refractive correction by creating corneal stromal collagen tissue with fibril diameter and spacing that duplicates the optical transmission and diffusion characteristics of natural corneal collagen. The repair method includes implanting the collagen scaffold during laser corneal ablation or other interlamellar ... 07/20/06 - 20060159723 - Antimicrobial lenses and methods of their use This invention relates to antimicrobial lenses containing coated zeolites and methods for their production. ... 07/20/06 - 20060159722 - Layered aligned polymer structures and methods of making same This invention includes a method of producing a nanostructured artificial template comprising one or more thin, oriented layer of polymer material. The material is preferably produced by the method of introducing a shearing flow in a predominantly monomeric solution of the self-assembling polymer sub-units to the free surface of a ... 06/22/06 - 20060134177 - Amphiphilic block copolymers and their use The present invention relates to amphiphilic block copolymers comprising at least one block of hydrophilic units and at least one block of hydrophobic units, wherein at least one hydrophobic block contains siloxane units. The present invention may be particularly useful as a tissue adhesive or as a coating for an ... 06/22/06 - 20060134176 - Pharmaceutical delivery system and method of use The present invention includes a pharmaceutical delivery system comprising a fused pyrrolocarbazole and a pharmaceutical delivery device that is selected from the group consisting of reservoir device and drug infusion device. The pharmaceutical delivery systems are sized and configured to be inserted into the eye of the patient. ... 06/22/06 - 20060134175 - Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use The present invention includes a pharmaceutical delivery system comprising a fused pyrrolocarbazole and a drug-eluting polymer matrix configured to be inserted into the eye of the patient. ... 06/22/06 - 20060134174 - Pharmaceutical delivery system and method of use The present invention includes a pharmaceutical delivery system comprising a fused pyrrolocarbazole and a biodegradable polymer matrix configured to be inserted into the eye of the patient. ... 06/22/06 - 20060134173 - Polysiloxanes, method of synthesis and ophthalmic compositions A linear polysiloxane copolymer has at least one terminal hydroxyalkyl group. The copolymer is preparable by a process comprising a combination of a base-catalysed polymerisation with an acid-catalysed redistribution, and is suitable for preparing ophthalmic compositions for forming an intraocular lens in situ. ... 06/22/06 - 20060134172 - Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (lox) and lox-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of lysyl oxidase (LOX) or a lysyl oxidase-like protease (LOXL). ... 06/22/06 - 20060134171 - Agents which regulate, inhibit, or modulate the activity and/or expression of formyl peptide receptors as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of FPR. ... 06/22/06 - 20060134170 - Vision enhancing ophthalmic devices and related methods and compositions Devices, methods, and compositions for improving vision or treating diseases, disorders or injury of the eye are described. Ophthalmic devices, such as corneal onlays, corneal inlays, and full-thickness corneal implants, are made of a material that is effective in facilitating nerve growth through or over the device. The material may ... 06/22/06 - 20060134169 - Polymerizable surfactants and their use as device forming comonomers This invention describes the use of polymerizable surfactants as comonomers in forming ophthalmic devices such as contact lenses, intraocular lenses, corneal implants, etc. ... 06/15/06 - 20060127446 - Apparatus and method for delivering controlled quantities of one or more agents to the eye A flat strip of supporting material, such as filter paper, having marked reference locations on each of one or more legs, for delivering controlled quantities of one or more agents to the adnexa of the eye simultaneously upon dispensing a liquid to the strip at the appropriate reference location. ... 06/08/06 - 20060121090 - Ocular compositions that increases the activity of gelatinase a in ocular cells Compositions capable of effecting a “pharmacological trabeculocanalotomy” in an eye by means of reducing juxtacanalicular meshwork as a barrier to outflow of aqueous. The small organic molecules increase Gelatinase A activity in ocular cells by increasing cell membrane expression of membrane-type matrix metalloproteinases (MT-MMPs) to increase aqueous outflow as a ... 05/25/06 - 20060110429 - Implant for intraocular drug delivery An implant for intraocular drug delivery for the treatment of inflammatory or degenerative diseases. In one embodiment, the implant includes a body portion having a first end portion and a second, opposite end portion and defining a cavity with a first opening at the first end portion, and a second, ... 05/25/06 - 20060110428 - Methods and devices for the treatment of ocular conditions Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device ... 05/25/06 - 20060110427 - Ophthalmic compositions comprising polyether substituted polymers The present invention relates to ophthalmic solutions and devices comprising at least one water soluble polymer having a molecular weight of at least about 500,000 Daltons and comprising linear or branched polyether pendant groups having a molecular weight of at least about 300. ... 04/20/06 - 20060083774 - Neurophilin ligands for treating ocular conditions The use of neurophilin ligands for treating glaucoma and lowering IOP is disclosed. ... 04/20/06 - 20060083773 - Artificial corneal implant A material that can be applied as implants designed to artificially replace or augment the cornea, such as an artificial cornea, corneal onlay, or corneal inlay (intrastromal lens) is provided. The artificial corneal implant has a double network hydrogel with a first network interpenetrated with a second network. The first ... 04/13/06 - 20060078592 - Drug delivery systems A method for making an ocular drug delivery device involves subjecting the device to a supercritical fluid to remove contaminants from the device. The supercritical fluid includes supercritical carbon dioxide. The contaminants include unreacted monomers or oligomers present in the polymeric material used to form the device. ... 04/06/06 - 20060073185 - Method and composition for contact lenses A solution for soft, hydrogel contact lenses includes a polyether that is controllably released into an eye's tear film when the lens is worn. Polyether components of the subject solution are released from the soft contact lens material matrix over long time periods to produce longer lasting wetting performance, improved ... 04/06/06 - 20060073184 - Viscoelastic composition, methods of use and packaging device with anti-oxidant The present invention is directed to a viscoelastic composition comprising an aqueous solution having a viscoelastic polymer based upon the total volume of the viscoelastic composition. Typically, the viscoelastic composition further contains soluble vitamin derivative. The present invention also includes methods of use of the new viscoelastic composition and a ... 03/30/06 - 20060067980 - Capsule for encasing tablets for surgical insertion into the human body A drug delivery device for placement in a body includes a drug core comprising a pharmaceutically active agent, and a holder that holds the drug core. The holder is made of a material impermeable to passage of the active agent and includes at least one opening for passage of the ... 03/30/06 - 20060067979 - Ophthalmic drug release device for multiple drug release A drug delivery device for placement in the eye includes a drug core comprising a pharmaceutically active agent, and a holder that holds the drug core. The holder is made of a material impermeable to passage of the active agent and includes an opening for passage of the pharmaceutically agent ... 03/30/06 - 20060067978 - Process for preparing poly(vinyl alcohol) drug delivery devices The present invention is a process for making a plurality of drug delivery devices for implantation in the eye of a patient. The plurality of drug delivery devices are made in part of poly(vinyl alcohol). During the manufacturing process the poly(vinyl alcohol) is cured. The poly(vinyl alcohol) may be in ... 02/23/06 - 20060039952 - Ophthalmic drug delivery device Ophthalmic drug delivery devices useful for delivery of pharmaceutically active agents to the posterior segment of the eye are disclosed. The devices may include extensions, immobilizing structures, and/or geometries to help properly locate, and prevent migration of, the devices. ... 02/16/06 - 20060034892 - Composition for topical administration The present invention provides a composition for topical administration comprising an interleukin 2 inhibitor and an antimicrobial agent as active ingredients thereof, wherein said interleukin 2 inhibitor contains a tricyclo compound as shown by the general formula (I) or pharmaceutically acceptable salt thereof. The present invention further provides a method ... 02/16/06 - 20060034891 - Biodegradable controlled release bioactive agent delivery device The invention provides implantable medical devices that are fabricated, at least in part, from biodegradable polymeric material. The implantable medical devices are used to provide bioactive agent to a treatment site, and are particularly useful for treatment of limited access regions of the body. ... 02/16/06 - 20060034890 - Device for ocular delivery of active principles by the transpalpebral route The invention relates to a device for ocular delivery of active principle(s) (1) comprising a first outer layer (2) which is essentially non-leaking, and a second inner layer (3) which has a surface (7) able to come into contact with at least one eyelid. characterized in that the second layer ... 02/02/06 - 20060024350 - Biodegradable ocular devices, methods and systems The invention provides implantable medical devices that are fabricated of biodegradable materials for delivery of bioactive agent to limited access regions of a patient's body, such as the eye. The invention further provides methods of treatment utilizing the devices. ... 01/26/06 - 20060018949 - Injectable biodegradable drug delivery system Compositions for delivering a pharmaceutically active agent to the eye, and/or for treating an ophthalmic disorder, are based on a fumarate polymer, especially a poly(propylene fumarate) polymer. ... 01/19/06 - 20060013859 - Drug delivery system using subconjunctival depot The present invention provides a drug delivery system to a posterior segment wherein a pharmaceutical composition comprising a drug and a vehicle is administered subconjunctivally to form a depot out of the vehicle, and thereby the drug is gradually released from the depot to enable an effective concentration of the ... 01/19/06 - 20060013858 - Fludrocortisone treatment for hearing loss Methods and compositions for treating or stabilizing hearing loss due to cochlear disorders by administration of compositions that include fludrocortisone or a mimetic or analog thereof are disclosed. ... 01/12/06 - 20060008506 - Method for preparing therapeutic ophthalmic articles using compressed fluids The present invention describes a method for the impregnation of a drug or a drug composition into ophthalmic articles, in order to prepare drug sustained release systems mainly for the treatment of glaucoma and other eye diseases. Ophthalmic articles can be for example contact lenses. The drug or drug composition ... 01/05/06 - 20060002982 - Xanthan gum viscoelastic composition, method of use and package The present invention is a novel viscoelastic composition that includes a suitable aqueous carrier and xanthan gum. The novel viscoelastic composition has rheological properties consistent with a good dispersive viscoelastic and improved damping ability over commercial dispersive viscoelastics. ... 01/05/06 - 20060002981 - Hyaluronic acid in the enhancement of lens regeneration The present invention addresses the treatment of ocular conditions by the enhancement of lens regeneration. This is accomplished by the administration of a high viscosity composition including a hyaluronic acid compound. Excess high viscosity composition may be removed by focal laser photophacoablation. Additionally, a collagen product may be injected within ... 12/22/05 - 20050281863 - Controlled release bioactive agent delivery device The invention provides controlled release bioactive agent delivery devices that include a body member having a direction of extension, a longitudinal axis along the direction of extension, and a proximal end and a distal end, wherein at least a portion of the body member deviates from the direction of extension, ... 12/22/05 - 20050281862 - Non-aspirating transitional viscoelastics for use in surgery Non-aspirating viscoelastics, compositions, and methods of use are disclosed. The non-aspirating, transitional viscoelastics possess sufficient viscosity to be useful in ophthalmic viscosurgery, but may be left in the eye with little or no resulting IOP spike. The compositions are particularly useful in cataract surgery. ... 12/22/05 - 20050281861 - Macromolecule-containing sustained release intraocular implants and related methods Biocompatible intraocular drug delivery systems include a non-neurotoxic macromolecule therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The macromolecule therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain ... 12/08/05 - 20050271706 - Controlled release bioactive agent delivery device The invention provides methods for delivering bioactive agent to an eye, the methods including steps of providing a device at an implantation site within the eye, and maintaining the device at the implantation site to provide a therapeutically effective amount of the bioactive agent to the eye. The device includes ... 12/08/05 - 20050271705 - Retinoid-containing sustained release intraocular drug delivery system and related methods Biocompatible intraocular implants include a retinoid component and a biodegradable polymer that is effective to facilitate release of the retinoid component into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is ... 12/08/05 - 20050271704 - Injectable glaucoma implants with multiple openings Intraocular stents and applicators are disclosed for treating glaucoma. The stents are configured to extend between the anterior chamber of the eye and Schlemm's canal for enhancing outflow of aqueous from the anterior chamber so as to reduce intraocular pressure. The stents can have features for anchoring the stent into ... 12/01/05 - 20050266047 - Injectable glaucoma implants with multiple openings Intraocular stents and applicators are disclosed for treating glaucoma. The stents are configured to extend between the anterior chamber of the eye and Schlemm's canal for enhancing outflow of aqueous from the anterior chamber so as to reduce intraocular pressure. The stents can have features for anchoring the stent into ... 11/24/05 - 20050260249 - Antimicrobial contact lenses and methods for their production where R1, R2 are defined herein and the ratio of silver to is at least about 0.6. ... 11/17/05 - 20050255143 - Method of use of carboxylated polysaccharides topically on the eyeball The use of chemically modified dicarboxy polysaccharides for the topical treatment of the eyeball are described. The modified polysaccharides provide a carrier in solutions for the treatment of the eyeball to obtain a timed release. ... 11/10/05 - 20050249778 - Carboxylated polysaccharides and method of preparation and use Chemically modified dicarboxy polysaccharides are described. The modified polysaccharides are useful as a carrier for cosmetics, pharmaceuticals, veterinary products and the like. The modified polysaccharides can provide a timed release of active ingredients. ... 11/03/05 - 20050244477 - Tyrosine kinase microsphers Biocompatible intraocular microspheres include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the microspheres can be associated with a biodegradable polymer matrix, such ... 11/03/05 - 20050244476 - Intraocular implants and methods for improving vision Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, ... 11/03/05 - 20050244475 - Biodegradable intravitreal tyrosine kinase implants Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such ... 11/03/05 - 20050244474 - Steroid-containing sustained release intraocular implants and related methods Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable ... 11/03/05 - 20050244473 - Memantine intravitreal implants Biocompatible intraocular implants include an anti-excitotoxic agent and a biodegradable polymer that is effective to facilitate release of the anti-excitotoxic agent into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is ... 11/03/05 - 20050244472 - Intraocular drug delivery systems containing excipients with reduced toxicity and related methods Drug delivery systems suitable for administration into the interior of an eye of a person or animal are described. The present systems include one or more components which are effective in improving a release profile of a drug from the system, improving the stability of the drug, and improving the ... 11/03/05 - 20050244471 - Estradiol derivative and estratopone containing sustained release intraocular implants and related methods Biocompatible intraocular implants include an anti-angiogenic agent, such as estradiol derivative or an estratopone and a biodegradable polymer that is effective to facilitate release of the anti-angiogenic agent into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer ... 11/03/05 - 20050244470 - Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix ... 11/03/05 - 20050244469 - Extended therapeutic effect ocular implant treatments Methods for treating ocular conditions by inserting an implant comprising an active agent into an ocular site of a patient thereby obtaining an amelioration of a symptom of the ocular condition (i.e. a therapeutic effect) for an extended period of time during which a therapeutic amount or a detectable amount ... 11/03/05 - 20050244468 - Sustained release intraocular implants and related methods Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable ... 11/03/05 - 20050244467 - Extended release biodegradable ocular implants Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer. ... 11/03/05 - 20050244466 - Photodynamic therapy in conjunction with intraocular implants A method for treating an ocular condition is provided. The method includes the steps of placing into an eye, a bioerodible implant comprising an anti-inflammatory component and a bioerodible polymeric component in order to provide extended dosing of anti-inflammatory agent to the eye, and treating the eye with photodynamic therapy. ... 11/03/05 - 20050244465 - Drug delivery systems and methods for treatment of an eye Systems and methods are provided for treatment of an eye. The systems generally include controlled, delayed and or sustained release bioerodible implantable elements having multiple layers of different materials and/or different concentrations of materials. The elements generally include an inner layer, or core, including a therapeutic agent, and one or ... 11/03/05 - 20050244464 - Hypotensive lipid-containing biodegradable intraocular implants and related methods Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. ... 11/03/05 - 20050244463 - Sustained release intraocular implants and methods for treating ocular vasculopathies Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, ... 11/03/05 - 20050244462 - Devices and methods for treating a mammalian eye Devices and methods for delivering a therapeutically active ocular implant into an eye are provided. Such a device generally includes a hollow sleeve having an open proximal end, a distal end, a substantially uniform inner diameter and a substantially uniform outer diameter extending between the proximal end and the open ... 11/03/05 - 20050244461 - Controlled release drug delivery systems and methods for treatment of an eye Systems and method are provided for treatment of an eye. The systems generally include controlled release implantable elements including a therapeutic component and a substantially inactive matrix component. The systems include such elements having controlled porosities and/or controlled surface roughness. The elements are typically bioerodible and structured to be implantable ... 10/27/05 - 20050238692 - Biomedical adhesive The biomedical adhesives of the invention provide a reactive surface to adhere or crosslink to tissue and may be used, for example, as ready-to-use corneal onlay in ophthalmic surgery. The invention provides a method for bonding a bulk material to a corresponding nucleophilic or electrophilic surface including attaching a multifunctionally ... 10/20/05 - 20050232972 - Drug delivery via punctal plug A method and apparatus for administering an active agent such as a medicine to a subject, uses an ocular implant such as a punctal plug, to which the active agent has been applied. The implant is installed at the eye of the subject for administering the active agent via tissues ... 09/29/05 - 20050214345 - Artificial biocompatible material as a support for cells in a retinal implant A retinal implant is provided that uses an artificial biocompatible material as a support material on which retinal pigment epithelial cells, iris pigment epithelial cells, and/or stem cells can be deposited either in situ or in vivo. The support material has a surface topology that is rough to promote cell ... 09/22/05 - 20050208103 - Targeted transscleral controlled release drug delivery to the retina and choroid The invention provides methods for delivering a therapeutic or diagnostic agent to the eye of a mammal. The method involves contacting sclera with a therapeutic or diagnostic agent so as to permit its passage through the sclera into the choroidal and retinal tissues. The sclera may be contacted with a ... 09/22/05 - 20050208102 - Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases This invention provides a polymeric drug delivery system including a hydrogel containing one or more drugs for the treatment of a posterior segment disease. Allowing passive transference of this drug from a dilute solution into the hydrogel produces the delivery system. The hydrogel, when placed in contact with the eye, ... 09/08/05 - 20050196427 - Engineered proteins, and methods of making and using The present invention provides engineered proteins and biomedical products made from the engineered proteins. The biomedical products include lenses useful for ophthalmic purposes. ... 09/01/05 - 20050191335 - Ophthalmic lenses and compositions and methods for producing same Ophthalmic lenses, such as corneal contact lenses, include a lens body made of a composition including a lens body made of a composition including a first crosslinked polymer material which is water swellable, and a second polymeric material, other than the first material, selected from water soluble polymeric materials, water ... 08/18/05 - 20050181018 - Ocular drug delivery An ocular device that contains a drug, the device affixed to the sclera for release of drug into the sclera through at least one opening. Control of drug release may be mechanical and/or electrical, and may be at a point of use or from a remote location. In one embodiment, ... 08/18/05 - 20050181017 - Compositions and methods for localized therapy of the eye Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye. ... 07/21/05 - 20050158365 - Drug delivery device with mechanical locking mechanism A drug delivery device for placement in the eye includes a drug core comprising a pharmaceutically active agent, and a holder that holds the drug core. The holder is made of a material impermeable to passage of the active agent and includes at least one opening for passage of the ... 07/14/05 - 20050152951 - Liquid, eye-instillable preparations comprising sodium hyaluronate A liquid, eye-instillable preparation comprises a viscosity-enhancing agent comprised of one or both of sodium hyaluronate and chondroitin sulphate, a preservative comprised of polyhexanide, and one or more carriers in which the agent and the preservative are dispersed. ... 06/23/05 - 20050136095 - Drug delivery device with suture ring A drug delivery device for placement in the eye includes a drug core comprising a pharmaceutically active agent, and a holder that holds the drug core. The holder is made of a material impermeable to passage of the active agent and includes an opening for passage of the pharmaceutically agent ... 06/23/05 - 20050136094 - Drug delivery device with mesh based suture tab A drug delivery device for placement in the eye includes a drug core comprising a pharmaceutically active agent, and a holder that holds the drug core. The holder is made of a material impermeable to passage of the active agent and includes an opening for passage of the pharmaceutically agent ... 06/02/05 - 20050118231 - Solid dosage form for the ocular administration of an active principle, a soluble, solid ophthalmic insert and the production method thereof A solid dosage form for the ocular administration of an active principle includes at least one biocompatible, water-soluble excipient for ophthalmic use. The form is obtained using a method which is selected from among the following: direct compression, dry compression, wet compression, compression of a lyophilizate, the compression being carried ... ### FreshPatents.com Support |